<div id="readability-page-1"><p>Organogenesis (NASDAQ:ORGO - Get Free Report) shares rose 6.2% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $7.00 to $9.00. BTIG Research currently has a buy rating on the stock. Organogenesis traded as high as $5.48 and last traded at $5.4350. Approximately 215,220 shares traded hands during trading, a decline of 85% from the average daily volume of 1,433,693 shares. The stock had previously closed at $5.12.</p><p>ORGO has been the topic of several other reports. Cantor Fitzgerald raised their target price on Organogenesis from $7.00 to $9.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 8th. Wall Street Zen raised shares of Organogenesis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday, November 8th. Finally, Weiss Ratings  reiterated a &#34;sell (d+)&#34; rating on shares of Organogenesis in a research report on Thursday, November 13th. Two analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to data from MarketBeat.com, the stock  has an average rating of &#34;Hold&#34; and a consensus price target of $8.00.</p><div><p><span></span><span>Get <strong>Organogenesis</strong> alerts:</span></p></div><p><b>View Our Latest Research Report on Organogenesis</b></p><h2>Hedge Funds Weigh In On Organogenesis</h2><p>Large investors have recently made changes to their positions in the business. Trexquant Investment LP purchased a new stake in shares of  Organogenesis in the 1st quarter worth approximately $516,000.  Assenagon Asset Management S.A. boosted its holdings in  Organogenesis by 748.1% in the second quarter. Assenagon Asset Management S.A. now owns 2,857,904 shares of the company's stock worth $10,460,000 after acquiring an additional 2,520,941 shares in the last quarter.  Cerity Partners LLC boosted its holdings in  Organogenesis by 48.2% in the first quarter. Cerity Partners LLC now owns 74,880 shares of the company's stock worth $323,000 after acquiring an additional 24,362 shares in the last quarter.  Vanguard Group Inc. grew its stake in shares of  Organogenesis by 23.4% in the first quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock worth $19,144,000 after acquiring an additional 841,618 shares during the last quarter.  Finally, Connor Clark &amp; Lunn Investment Management Ltd. increased its holdings in shares of  Organogenesis by 45.3% during the first quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 667,529 shares of the company's stock valued at $2,884,000 after acquiring an additional 208,038 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Organogenesis Price Performance</h2><p>The firm has a fifty day moving average price of $4.61 and a two-hundred day moving average price of $4.27. The company has a quick ratio of 2.88, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $696.10 million, a P/E ratio of -45.54 and a beta of 1.68. </p><p>Organogenesis (NASDAQ:ORGO - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to the consensus estimate of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%.  Organogenesis has set its FY 2025 guidance at  EPS. On average, analysts expect that  Organogenesis will post -0.07 EPS for the current year. </p><h2>About Organogenesis</h2> (Get Free Report)<p>Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.</p><h2>Read More</h2><ul><li>Five stocks we like better than Organogenesis</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>4 High-Risk Growth Stocks Under $15 to Watch This Fall</li><li>CD Calculator: Certificate of Deposit Calculator </li><li>Walmart Stock Surges After a Solid Q3—Stronger Growth Ahead</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>Microsoft’s AI Superfactory Could Power a Stock Rally</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Organogenesis Right Now?</h2><p>Before you consider Organogenesis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.</p><p>While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ORGO

<p>Organogenesis (NASDAQ:ORGO) shares rose 6.2% after BTIG Research upgraded its price target from $7.00 to $9.00, maintaining a buy rating. The stock traded at $5.48, with a decline in trading volume. Analysts have mixed ratings, with a consensus price target of $8.00. Hedge funds have increased their holdings, owning 49.57% of the stock. Organogenesis reported better-than-expected quarterly earnings, with revenue of $150.86 million.</p>

Organogenesis (NASDAQ:ORGO) Trading Up 6.2% on Analyst Upgrade